1-%<& ,
+)1-%& I, p.1 ,
W)'1+%&h'%&#, <&#%<&'1$1+%<&B+"W'1%<&*)$O+%&+%/,&#%&'N%CC%*+1C&hme&B%&q&%+&[eX& /Hb$>iL&>"&$)K%//%&#%<CCB-%/*%<&%<+&O-)*D%&#%&q&hAa9MU&/Hb$>i&%+&*%''%&#%<&-"OO)-+<& O-)*D%&#%&p&hq9oXiL& ,
<<%<& h0, %&h4 M &Ç&q9[aiL&>%&H-"OD1T,%& & & pXa& *1A#%<<)+1)/&#%<&*) ,
&J%-01*%&hG, R& A& !%<,-%<&ODK<1T,%<&-B"'1<B%<&O"-&I ,
1<& #y1, +1L& @%++%& hO%+1+%i& 0"-1"+1) ,
&Q)/%&qAUq&/Hb$>&)Ü&'N%CC%+&ODK<1)'), &T,1&%<+&-"O1#%9& C"*1'%$%/+& #1<O)/1W'%9& C1"W'%& %+& O%,& *)á+%,<%&O%,+&V+-%&,+1'1<B%&O)&H%<+1)/&#%<&O"+1%/+<9&Y&*)/#1+1)/&T,%&'"&Q)/%&H-1<%&qA ,
<&#%&'1$1+%<&#%&@S&B+W1'1+B&uamv&0)1-%&$V$%&Mq&}&uoqvL&>%&#)<"H%&#%<&+, +1)/<L&I)<&@S&<,-&'%<&#%,R& ",+)$"+%<& <%& <1+,%/+& %/+-%& X9m& %+& m9p& }L& >%<& @S& <)/+&+1)/&#%<&*)+1)/<&W"<<%<&$"1<&-%<+%/+&O"-C"1+%$%/+&"**%O+"W'%<L&@)$O+%& ,
Hb$>&h;?Fi&uX[vuopvL&& & >"&'1$1+%&#%&'1, -%& #%& q& Y& maq& /Hb$>L& >%& +%$O<& #%& +D-)$W1/%& #1',B& "OO ,
H, 1<)/& & %<+& O% ,
H9&H, &%+&p&8Fb$>& #N;I3) hJ),-*%&s&#)<"H%<&-B"'1<B<&H1%&#,&@;8&#%&7)-#%, p.1 ,
*+1C&?-1/1@>E?x&31W-1, +&h$B+D)#%&#%&@'",<<iL& & & & pee& </V/ %CFG8)G8)DB)JCBNEDEC7), pp.1-1 ,
1/%<& uopv& 0)1-%& O',<1%,-<& $)1<& ueavL& I, +1)/& <,-& *%<& $%<,-%<& C)/*+1) ,
W1'1<"+1)/& h#%<&, 1T,N1'& %/& <)1+9& '%<& -B<,'+"+<& #%<& %<<"1<& #%& <+"W1'1+B&<)/+&<"+1<C"1<"/+<&O),-&'%&@IL& & & pem& 1L6]DFJEL6) ,
H, +1&DBO"+1T,%9&#%&O)1#<&%R+-V$%9&'%&$)/1+)-"H%&#%<&*)1<%-& <1& O)<<1W'%& Y& #1<+"/*%& #%& '"& O-1<%& #,& $B#1*"$%/+9& *N%<+& Y& #1-%& %/& -B<1#,%'L& 5/& %CC%+9&'%<&$%<+1)/&uoXvL&@%O% ,
+)1-%& h.F;:i& "& B+, +1T,%<&uoevL&G1/<19&'%&-1<T,%&DB$)--"H1T,%&%<+& *)/<1#B-B&*)$$%&C"1W'%&%/&*"<&#%&*)+1)/&1/CB-1%,-%&Y&Uq& ,
iL& F'& %<+& 1$O), p.1 ,
H, +1*)"H ,
1<B<& h?:9& ?@G9& ?@c9& C1W-1, <&#%&*%++%&%<+1$"+1)/L&>"&0"'1#"+1)/&#%&*%<&$B+D)#%<&#%&#)<"H%&"&#)/*&%,& ,/&1$O"*+&C1BH'1H%"W'%&<,-&'%&W,#H%+&#,&'"W)-"+)1-%L& & & pmp& +#+?#,A&-23#%) ,
La biologie médicale libérale en France!: bilan et perspectives Rapport pour un projet de réforme de la biologie médicale. Paris, ministère de la Santé, de la Jeunesse, des Sports et de la Vie associative NF EN ISO 15189-Laboratoires d'analyses de biologie médicale - Exigences particulières concernant la qualité et la compétence, NF EN ISO 22870-Analyses de biologie délocalisées (ADBD) -Exigences concernant la qualité et la compétence, 2006. ,
Nouveaux anticoagulants par voie orale: quelle place pour les analyses de biologie médicale?, STV Sang Thromb. Vaiss, vol.23, issue.1, pp.8-17, 2011. ,
Identification of Carboxylesterase-Dependent Dabigatran Etexilate Hydrolysis, Drug Metabolism and Disposition, vol.42, issue.2, pp.201-206, 2014. ,
DOI : 10.1124/dmd.113.054353
Dabigatran Etexilate: A New Oral Thrombin Inhibitor, Circulation, vol.123, issue.13, pp.1436-1450, 2011. ,
DOI : 10.1161/CIRCULATIONAHA.110.004424
The new oral anticoagulants, Blood, vol.115, issue.1, pp.15-20, 2010. ,
DOI : 10.1182/blood-2009-09-241851
The mechanism of action of rivaroxaban ??? an oral, direct Factor Xa inhibitor ??? compared with other anticoagulants, Thrombosis Research, vol.127, issue.6, pp.497-504, 2011. ,
DOI : 10.1016/j.thromres.2010.09.008
Sample Integrity and Preanalytical Variables, Quality in Laboratory Hemostasis and Thrombosis essor Vice Chair for Clinical Affairs, pp.31-42, 2008. ,
DOI : 10.1002/9781444303575.ch4
Les nouveaux anticoagulants oraux directs : r??le du laboratoire d???h??mostase, Revue Francophone des Laboratoires, vol.2014, issue.463, pp.37-51, 2014. ,
DOI : 10.1016/S1773-035X(14)72523-7
New anticoagulants: Moving on from scientific results to clinical implementation, Annals of Medicine, vol.37, issue.1 ,
DOI : 10.1161/01.CIR.0000038501.87442.02
Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to ,
On the monitoring of dabigatran treatment in ???real life??? patients with atrial fibrillation, Thrombosis Research, vol.134, issue.4, pp.783-789, 2014. ,
DOI : 10.1016/j.thromres.2014.06.016
Suivi biologique des patients sous nouveaux anticoagulants oraux!: qui, quand, comment!?, Feuill. Biol, vol.LV, issue.319, 2014. ,
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate ,
Hillarp, and Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays ,
The new oral anticoagulants and the future of haemostasis laboratory testing, Biochemia Medica, pp.329-341, 2012. ,
DOI : 10.11613/BM.2012.035
Manotti, and Italian Federation of Thrombosis Centers Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA), Thromb. Haemost, vol.106, issue.5, pp.868-876, 2011. ,
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement, Thrombosis Research, vol.127, issue.5, pp.457-465, 2011. ,
DOI : 10.1016/j.thromres.2011.01.001
Role of meizothrombin and meizothrombin-(Des F1) in the conversion of prothrombin to thrombin by the Echis carinatus venom coagulant, Biochemistry, vol.21, issue.14, pp.3437-3443, 1982. ,
DOI : 10.1021/bi00257a029
The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors, Pathophysiology of Haemostasis and Thrombosis, vol.33, issue.4, pp.173-183, 2003. ,
DOI : 10.1159/000081505
Ecarin Chromogenic Assay ??? A New Method for Quantitative Determination of Direct Thrombin Inhibitors Like Hirudin, Pathophysiology of Haemostasis and Thrombosis, vol.33, issue.4, pp.184-191, 2003. ,
DOI : 10.1159/000081506
Newer oral anticoagulants: A review of laboratory monitoring options and reversal agents in the hemorrhagic patient, American Journal of Health-System Pharmacy, vol.69, issue.17 ,
DOI : 10.2146/ajhp110725
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban, Cleveland Clinic Journal of Medicine, vol.80, issue.7, pp.443-451, 2013. ,
DOI : 10.3949/ccjm.80a.13025
Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays Which Assay Is Helpful?, Am. J. Clin. Pathol, vol.138, issue.4, pp.551-558, 2012. ,
Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay, Annals of Pharmacotherapy, vol.47, issue.12, pp.1635-1640, 2013. ,
DOI : 10.1016/j.thromres.2011.01.001
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran, Blood Coagulation & Fibrinolysis, vol.23, issue.2, pp.138-143, 2012. ,
DOI : 10.1097/MBC.0b013e32834f1b0c
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study, J ,
Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature, Thrombosis Research, vol.130, issue.6, pp.956-966, 2012. ,
DOI : 10.1016/j.thromres.2012.09.004
Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature, Thrombosis Research, vol.130, issue.6, pp.956-966, 2012. ,
DOI : 10.1016/j.thromres.2012.09.004
Measuring oral direct inhibitors of thrombin and factor??Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, vol.123, issue.4 ,
DOI : 10.1111/jth.12149
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in??vitro study, Journal of Thrombosis and Haemostasis, vol.8, issue.1 ,
DOI : 10.1111/j.1538-7836.2010.04106.x
Assessment of laboratory assays to measure rivaroxaban ??? an oral, direct factor Xa inhibitor, Thrombosis and Haemostasis, vol.103, issue.4, pp.815-825, 2010. ,
DOI : 10.1160/TH09-03-0176
Clinical laboratory measurement of & & pma& direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay ,
Rivaroxaban and Apixaban in Orthopedics: is there a difference in their plasma concentrations and anticoagulant effects!?, Blood Coagul. Fibrinolysis, 2015. ,
Makris, and the BCSH committee Measurement of non-Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology ,
Is Dilute Russell's Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?, Blood, vol.122, issue.21, pp.3634-3634, 2013. ,
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thrombosis and Haemostasis, vol.110, issue.4, pp.543-549, 2013. ,
DOI : 10.1160/TH13-04-0274
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls, Thrombosis and Haemostasis, vol.107, issue.2, pp.379-387, 2011. ,
DOI : 10.1160/TH11-06-0391
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma, Thrombosis and Haemostasis, vol.104, issue.5, pp.1078-1079, 2010. ,
DOI : 10.1160/TH10-03-0204
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide, Thrombosis and Haemostasis, vol.110, issue.2, pp.283-294, 2013. ,
DOI : 10.1160/TH12-12-0898
Walenga, and for the & & pmX& working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis, Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH ,
Current databases on biological variation: pros, cons and progress, " Scand, J. Clin. Lab. Invest, vol.59, issue.7, pp.491-500, 1999. ,
ACL TOP® Family Analytical Precision Performance Requirements, 2013. ,
Guideline on bioanalytical method validation, 2011. ,
Inherent biological variation and reference values, Clinical Chemistry and Laboratory Medicine, vol.42, issue.7 ,
DOI : 10.1515/CCLM.2004.128
Réflexion sur le choix des limites acceptables dans les programmes d'évaluation externe de la qualité, Ann. Biol. Clin. (Paris), vol.65, issue.6, pp.677-684, 2007. ,
Analyses de biologie médicale!: spécifications et normes d'acceptabilité à l'usage de la validation de techniques ,
Determination of dabigatran, rivaroxaban and apixaban by UPLC-MS/MS and coagulation assays for therapy monitoring of novel direct oral anticoagulants, J ,
Confirmatory reanalysis of incurred bioanalytical samples, The AAPS Journal, vol.9, issue.3, pp.336-343, 2007. ,
DOI : 10.1208/aapsj0903040
Measuring agreement in method comparison studies, Statistical Methods in Medical Research, vol.8, issue.2, pp.135-160, 1999. ,
DOI : 10.1191/096228099673819272
Comparaison de deux m??thodes de mesure d'une m??me grandeur??: m??thode de Bland et Altman, Annales Fran??aises d'Anesth??sie et de R??animation, vol.19, issue.2, pp.128-135, 2000. ,
DOI : 10.1016/S0750-7658(00)00109-X
Etude des interférences de l'hémoglobine, de la bilirubine et des lipides sur 53 paramètres de biochimie, 1970. ,
Recommandations pour l'accréditation des Laboratoires de!: Phase pré-analytique -Phase analytique, Biologie Médicale, vol.1 ,
Interference Testing, Clin. Biochem. Rev, vol.29 ,
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, J. Thromb ,
Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50 µL rat plasma and its application to pharmacokinetic study, J ,
Development and validation of LC???MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma, Journal of Chromatography B, vol.989, pp.37-45, 2015. ,
DOI : 10.1016/j.jchromb.2015.02.042
Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry, J ,
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, British Journal of Clinical Pharmacology, vol.324, issue.3, pp.292-303, 2007. ,
DOI : 10.1345/aph.1D565
Dabigatran Acylglucuronide, the Major Human Metabolite of Dabigatran: In Vitro Formation, Stability, and Pharmacological Activity, Drug Metabolism and Disposition, vol.38, issue.9, pp.1567-1575, 2010. ,
DOI : 10.1124/dmd.110.033696
Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d'intérêt en Hémostase Périopératoire (GIHP) -mars 2013, Ann. Fr. Anesth. Réanimation, vol.32, issue.10, pp.691-700, 2013. ,
Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate, Thrombosis and Haemostasis, vol.110, issue.3, pp.543-549, 2013. ,
DOI : 10.1160/TH13-03-0202
Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay, Annals of Pharmacotherapy, vol.47, issue.12, pp.1635-1640, 2013. ,
DOI : 10.1016/j.thromres.2011.01.001
Determination of rivaroxaban ??? a novel, oral, direct Factor Xa inhibitor ??? in human plasma by high-performance liquid chromatography???tandem mass spectrometry, Journal of Chromatography B, vol.872, issue.1-2, pp.43-50, 2008. ,
DOI : 10.1016/j.jchromb.2008.07.015
LC???MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column, Bioanalysis, vol.6, issue.15, pp.2071-2082, 2014. ,
DOI : 10.4155/bio.14.66
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thrombosis and Haemostasis, vol.110, issue.4, pp.543-549, 2013. ,
DOI : 10.1160/TH13-04-0274
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin, Thromb. Haemost, vol.108, issue.1, pp.191-198, 2012. ,
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 ,
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thrombosis and Haemostasis, vol.110, issue.4, pp.723-731, 2013. ,
DOI : 10.1160/TH13-04-0274
Albumin: Structure, Function and Uses, 2014. ,
SH GTA 06-Guide technique d'accréditation!: contrôle de qualité en biologie médicale, 2012. ,
Fit-for-purpose method development and validation for successful biomarker measurement, Pharm. Res, vol.23, issue.2, pp.312-328, 2006. ,
UPLC MS/MS assay for routine quantification of dabigatran ??? A direct thrombin inhibitor ??? In human plasma, Journal of Pharmaceutical and Biomedical Analysis, vol.58, pp.152-156, 2012. ,
DOI : 10.1016/j.jpba.2011.09.018
Dabigatran étexilate et examens de biologie médicale, 2013. ,
Apixaban et examens de biologie médicale, 2013. ,
Rivaroxaban et tests de biologie médicale, 2012. ,
Le pr??-analytique en h??mostase et les recommandations du Groupe d?????tudes sur l???h??mostase et la thrombose (GEHT), Option/Bio, vol.20, issue.417, p.pp ,
DOI : 10.1016/S0992-5945(09)70113-8
Prise en charge d'un patient traité par dabigatran ou rivaroxaban, au long cours présentant une hémorragie ou nécessitant une chirurgie urgente, 2013. ,
Reversal of anticoagulants: an overview of current developments, Thrombosis and Haemostasis, vol.113, issue.5, 2015. ,
DOI : 10.1160/TH14-11-0982
Recent Advances in the Development of Specific Antidotes for Target-Specific Oral Anticoagulants, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.63, issue.Suppl, pp.198-207, 2015. ,
DOI : 10.1002/phar.1532
portola.com/clinical-development/andexanet-alfa-prt4445-fxa- inhibitor-antidote, 2015. ,
5:301.5'.!>!+::;.! 6+<&58123'!! 95:30185!1&:'&/1'! 930?'1,+&:'! 1&:'&/1'! =&:'&/1'! =&:'&/1'!&7&!/58':85! K5<0+, p.3 ,
00'30.!8':4&123'.!73! B17,7<123'.!>!'00'30, !:76A58'&:'.! >!I706+817&!:7&81&3'!>! 5?+,3+817&!/'!,+!I706+817&! :7&81&3'! ,
+3(! H05,;?'6'&8! S+3?+1, 7<1'!'8!A+8477&.! S+&23'!/'!I706+817&!/'.! 5231A'.! :,1&123'.>80+&.A708>8':4&123'!, pp.4-81 ,
:&*1!X!! :&*1!, SSR! :&*1!#! "UV! S(T! "RT! SWV! :&*1!"@&!)!-4%%/&*!-5!3+24.+14,.&!-7A/B4*1+*&C!AD0,1+3!<&33&6.,%C!8AE!-&!F4.-&+5'G! ! !"#$%&'$($)* +, p.45 ,
)*0)12345* =&/$1;/*%"#$%&'$($)*0)12345* ?&@;));*<, Annexe, vol.13, issue.1 ,
106-21'!4>?5.-3603'!'6!4'!@701.0,-9-;2'A!?B/2609!@'99';12&A!C?D!4'!E-14'08(F N-30, Annexe, vol.1690 ,
967!C7!5-,9*+-)!CD+)*J(,+O+C75!C+,9?7!, évaluation de l'interférence de la lactescence pour le dabigatran :L-9J&7!M!C-))?75!C9!, pp.66-78 ,
!1234)&.!0&!52!62, 54-*!0&.!/7+.&855&).!0&!597)0)&!0&, p.12 ,